A Randomized, Double-Blind, Phase 3 Trial of STA-4783 in Combination With Paclitaxel Versus Paclitaxel Alone for Treatment of Chemotherapy-Naive Subjects With Stage IV Metastatic Melanoma (SYMMETRY)
Latest Information Update: 02 Sep 2024
At a glance
- Drugs Elesclomol (Primary) ; Paclitaxel
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms SYMMETRY
- Sponsors Synta Pharmaceuticals
- 31 Aug 2024 This trial has been completed in Czechia according to European Clinical Trials Database record.
- 04 Jul 2012 Additional trial location (Spain) added as reported by European Clinical Trials Database record.
- 06 Jun 2010 One-year overall survival results have been presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).